Anti-mag IgM-associated demyelinating polyneuropathy

Clinical trials for Anti-mag IgM-associated demyelinating polyneuropathy explained in plain language.

Never miss a new study

Get alerted when new Anti-mag IgM-associated demyelinating polyneuropathy trials appear

Sign up with your email to follow new studies for Anti-mag IgM-associated demyelinating polyneuropathy, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Cancer drug could ease rare nerve disorder

Disease control Recruiting now

This study tests whether zanubrutinib, a drug used for certain blood cancers, can improve nerve function in people with anti-MAG neuropathy—a rare condition causing numbness, weakness, and balance problems. About 50 adults in Italy will take the drug for 12 months. Researchers wi…

Matched conditions: ANTI-MAG IGM-ASSOCIATED DEMYELINATING POLYNEUROPATHY

Phase 2 • Sponsor: Azienda Ospedaliera di Padova • Aim: Disease control

Last updated Aug 30, 2026 00:00 UTC

Anti-mag IgM-associated demyelinating polyneuropathy

Get alerted when new Anti-mag IgM-associated demyelinating polyneuropathy trials appear

Cancer drug could ease rare nerve disorder